Latest Novakand Pharma News & Updates
See the latest news and media coverage for Novakand Pharma. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of innovative drugs for inflammation and cancer
novakand.com- Company type
- Public company
- Number of employees
- 3–10
Last updated
Latest news about Novakand Pharma
In short: Novakand Pharma faced delisting from Nasdaq First North, canceled a merger with SVF Vaccines, and shifted focus back to its fractalkine program.
Company announcements
-
Novakand Pharma publishes annual report and corporate governance report for 2025
The documents are available on the company's website.
-
Novakand Pharma calls for annual general meeting
The annual general meeting is held on May 25, 2026 in Stockholm. Registration is required by May 19. Agenda includes annual report, discharge from liability and elections.
-
Novakand Pharma holds extraordinary general meeting
The meeting decides on focus on fractal kinase program, capital needs and special review of CEO, board and capital usage. The board makes seats available.
-
Novakand Pharma calls an extraordinary general meeting
The meeting is held on April 15, 2026 in Stockholm. Shareholders vote on reverse acquisition of SVF Vaccines or restart of the fractalkin program. Proposal for review of CEO and board.
Media coverage
-
MFN.se > Novakand Pharma > Novakand’s Board of Directors proposes new business direction and relisting to be presented at Extraordinary General Meeting
Background Novakand Pharma AB (”Novakand” or the ”Company”) announced on February 24, 2026, that Nasdaq had rejected Novakand's application for continued listing on First North...
-
BRIEF—SVF Vaccines intended merger with Novakand will not be carried out
KDventures has revealed that the planned reversed acquisition of the portfolio company SVF Vaccines by Novakand Pharma will not be completed, following Nasdaq’s rejection of...
-
The observation status for Novakand Pharma AB is updated
On November 25, 2025, the shares in Novakand Pharma AB (the "Company") were given observation status with reference to the Company's disclosure of its interim...
-
Karolinska Development’s portfolio company SVF Vaccines and Novakand Pharma enters into a reverse acquisition agreement
STOCKHOLM, Sweden, February 6, 2026. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces that its portfolio company SVF Vaccines has entered into a reverse acquisition agreement...
Track Novakand Pharma and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Trending companies
Discover what's making headlines across other trending companies.
Pit
Davis AI
Qutwo
DigiPowerX
Penguin Solutions
Sterling Infrastructure
KIOXIA Corporation
Subquadratic
Tibber
IREN
A24
Hitachi Energy
Ouster
Ormat Technologies
Fabrinet
AOI
WidePoint
Filtronic
Mirum Pharmaceuticals
Capstone Green Energy
AXT
POET Technologies
PurpleFire
Profitable Media
Sironax
Aperture Therapeutics
Attentive
Klaviyo
Twilio
Insider One
Zeta Global
Iterable
Braze
Optimove
Bluecore